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Abstract  Because  asthma  and  COPD  are  both  inﬂammatory  chronic  obstructive  airway  dis-
eases, there  are  several  clinical  expressions  which  can  cause  confusion,  such  as:  eosinophilic
asthma with  ﬁxed  obstruction,  which  is  a  risk  factor  and  might  progress  to  COPD;  eosinophilic
COPD; COPD  with  partial  reversible  obstruction  with  no  asthmatic  component  and  also
eosinophilic  asthma--COPD  overlap  syndrome  (ACOS).
While at  the  two  extremes  of  these  disorders  the  pathoimmunological  processes  are  clearly
different,  in  some  patients  there  is  overlap  and  the  pathophysiological  border  between  asthma
and COPD  is  fused  (or  diffuse).
The  current  guidelines  are  clearly  insufﬁcient  for  classiﬁcation  of  the  obstructive  patients
and, taking  into  account  that  binary  separation  between  the  two  diseases  is  not  completely
clear, we  should  resist  the  temptation  to  label  patients  as  ACOS  and  consider  new  airway
disease taxonomy.  Regardless  of  the  condition  concerned,  eosinophils  should  be  considered
in the  algorithm  approach  to  obstructive  patients:  in  COPD,  as  in  asthma,  they  are  related
to the  underlying  pathological  process;  they  have  prognostic  value  and  are  related  to  thera-
peutic response.  Therefore,  eosinophils  should  be  valued  as  useful  biomarkers  and  included
in a  multidimensional  diagnostic  and  therapeutic  approach,  bearing  in  mind  the  phenotypic,
immunopathological  and  functional  complexity  of  chronic  obstructive  airway  disease.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
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Asthma--Chronic  obstructive  pulmonary  disease  (COPD)
verlap  Syndrome  (ACOS)  has  been  regularly  used  to  cover
everal  clinical  events  that  are  hard  to  read  and  incorporate.
hereas  Asthma  and  COPD  are  both  chronic  inﬂammatory
nd  obstructive  diseases  of  the  airways,  the  obstructive  dis-
ase  can  manifest  itself  in  so  many  ways  that  it  can  be
onfusing,  both  within  the  clinical  spectrum  of  asthmatics
nd  in  COPD  patients.
On  the  one  hand,  among  the  independent  risk  factors
or  COPD,  personal  asthma  history  comes  up  as  relevant,
s  found  in  the  CANCOLD1 study  (which  followed  the  pro-
ocol  of  the  BOLD  study2).  On  the  other  hand,  the  clinical
henotype  of  asthma  with  ﬁxed  airﬂow  obstruction  is  well
nderstood  in  clinical  practice,  characterised  by  a  long  pro-
ression  time  of  the  disease,  frequently  lower  bronchial
yperreactivity  (HRB),  greater  disease  severity  and  usually
ith  raised  Th2-type  inﬂammation  markers  (such  as  Frac-
ion  of  exhaled  nitric  oxide  (FeNO),  sputum3 and  peripheral
lood  eosinophilia4),  of  predictive  value  for  that  phenotype.
Furthermore,  peripheral  blood  eosinophilia  is  also
resent  in  a  signiﬁcant  number  of  COPD  patients:  in  the
ohort  of  the  ECLIPSE  study  (Evaluation  of  COPD  Lon-
itudinally  to  Identify  Predictive  Surrogate  End-points5),
hich  included  approximately  1500  patients  with  COPD
nd  excluded  asthmatics,  the  prevalence  of  persistent
osinophilia  (deﬁned  as  eosinophils  in  blood  ≥2%  or
50  cells/microlitre)  was  37%.  This  patient  group  includes
ewer  smokers,  mostly  male  individuals,  who  enjoy
mproved  quality  of  life,  are  less  symptomatic  and  less  func-
ionally  impaired  (based  on  forced  expiratory  volume  in  the
rst  second  (FEV1)  assessment)  and  evolve  less  to  emphy-
ema  during  follow-up.
Finally,  according  to  the  CHAIN  study6 (multi-centre
atabase  of  well-characterised  COPD  patients),  with  one-
ear  follow-up,  which  did  not  exclude  asthmatics  and
ollowed  current  criteria  for  deﬁning  ACOS),  eosinophilia
xists  irrespective  of  asthma  overlap.  In  this  study,  27%  of
atients  who  suffered  from  COPD  but  did  not  have  ACOS,  had
eripheral  blood  eosinophils  above  3%.  Interestingly,  com-
aring  COPD  patients  with  and  without  ACOS,  parameters
ike  age,  chronic  bronchitis  symptoms,  emphysema  and  FEV1
id  not  differ  signiﬁcantly.
Consequently,  we  can  state  that  asthma  is  an  indepen-
ent  risk  factor  for  COPD  and  that  there  is  a  phenotype  of
sthma  with  persistent  obstruction,  which  is  more  severe
nd  has  eosinophilia  as  risk  factor  that  can  also  be  present
n  COPD,  irrespective  of  the  presence  of  asthma.
Therefore,  while  at  the  two  extremes  of  these  disorders
he  pathoimmunological  processes  are  clearly  different,  in
ome  patients  there  is  overlap  and  the  pathophysiological
order  between  asthma  and  COPD  is  fused  (or  diffuse).
This  brings  us  back  to  the  clash  between  British  vs.  Dutch
ypotheses,  which  support  the  different  or  common  origin
f  the  diseases,  respectively.
For  a  better  understanding  of  these  relationships  one
ust  identify  the  genes  involved,  their  epigenetic  interac-
ion  and  the  underlying  pathoimmunological  mechanisms  of
he  phenotypes  of  the  two  forms  of  the  disease.While  genome-wide  association  studies  (GWAS)  had  not
dentiﬁed  clear  associations  between  Asthma  and  COPD,7
ecent  evidence  underscores  the  shared  genetics.  A  cohort
tudy  of  individuals  from  the  UK  Biobank8 (the  largest
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uropean  Biobank),  which  grouped  the  sample  elements
ccording  to  extreme  FEV1 values  and  smoker  and  non-
moker  status,  found  that:  (i)  there  are  common  genetic
auses  for  airway  obstruction  in  smoker  and  non-smoker
atients  (and  that  genetics  and  smoking  habits  generally  act
ndependently);  (ii)  the  genetic  determinants  of  low  FEV1 in
on-asthmatic  individuals  are  also  involved  in  asthmatics;
iii)  there  is  a  fragment  of  the  gene  which  is  involved  in
irway  function  and  obstruction  in  the  general  population
17q21.31).
As  for  the  pathoimmunological  mechanisms,  a  very  ele-
ant  study  published  recently  by  the  Leicester  group9
upported  both  the  British  hypothesis  of  a  different  origin
f  the  two  diseases,  and  the  Dutch  hypothesis  that  points
o  a  common  origin.  This  study,  which  aimed  to  investigate
he  overlapping  pathophysiological  characteristics  between
sthma  and  COPD,  conducted  a  cluster  analysis  of  clini-
al,  physiological  and  cytokines  data  of  induced  sputum  in
evere  asthmatic  patients  and  individuals  with  moderate  to
evere  COPD.  Three  distinct  groups  were  identiﬁed:  one  with
redominantly  eosinophilic  asthma  and  Th2  cytokine  expres-
ion  (but  included  5%  of  patients  with  eosinophilic  COPD);
nother  of  predominantly  COPD  with  mixed  inﬂammation
nd  increased  IL-6  levels  in  the  sputum  (suggesting  the  dif-
erent  origin  of  the  two  diseases);  and  a  third,  composed
f  asthmatic  and  COPD  patients,  with  cytokine  IL-1 that
ifferentiated  it  from  the  other  two  (thus  supporting  the
ommon  origin).
Finally,  another  recent  study  found  the  Th2  proﬁle
enetic  signature  associated  with  ACOS  patients,  suppor-
ing  the  hypothesis  of  a  common  origin,  at  least  in  one
atient  phenotype.10 In  this  complex  investigation,  based
n  the  results  of  the  genetic  expression  study  of  asth-
atic  patients,  a  Th2  gene  expression  was  found  to  be
elated  to  increased  expression  of  Interleukin  (IL)  5  and  13  in
ronchial  biopsies,  higher  number  of  eosinophilis,  increased
ronchial  hyperreactivity  (HRB)  and  greater  response  to
nhaled  corticosteroids  (ICS).  In  the  same  study,  individu-
ls  with  the  same  Th2  gene  expression  were  found  in  the
ubsequent  analysis  of  two  COPD  patient  cohorts  of  that
tudy.  In  a  third  cohort  of  COPD  patients  (which  excluded
sthmatic  patients),  the  aforementioned  genetic  expression
as  associated  with  greater  disease  severity,  higher  num-
er  of  eosinophils  and  increased  response  to  ICS,  assessed
n  the  basis  of  residual  volume  (RV)  after  30  months  of
herapy.  It  is  thus  appropriate  to  state  that  these  indi-
iduals  with  COPD  and  signs  of  asthma,  whose  clinical
istory  did  not  suggest  asthma,  can  be  the  real  ACOS.  The
act  that  no  relation  with  FEV1 improvement  after  treat-
ent  was  found,  but  that  RV  did  decrease,  suggests  that
h2  gene  expression  inﬂuences  COPD  patients.  In  future
tudies,  other  outcomes  (like  RV)  should  be  used  besides
EV1.
Regardless  of  the  condition  concerned,  eosinophils  are
seful  biomarkers  in  chronic  obstructive  inﬂammatory  air-
ays  disease.11 Produced  in  the  bone  marrow  by  IL3  and  IL5
the  latter  being  responsible  for  prolonging  their  survival),
hey  migrate  to  the  airways  and  inﬁltrate  the  tissue  under
he  action  of  chemokines  and  integrins,  where  they  release
ationic  granule  proteins  and  cause  cell  damage,  increasing
xidative  stress,  while  exposing  the  epithelial  membrane,
ecoming  more  vulnerable.
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REosinophilic  COPD:  ACOS  or  COPD  phenotype?  
While  in  asthma  the  eosinophil  count  is  well  established,
now  is  the  time  to  assess  its  added  value  in  patients  diag-
nosed  with  COPD  (with  or  without  asthma).  The  value  of  a
biomarker  depends  on  the  relationship  with  the  patholog-
ical  process,  the  prognostic  value  and  the  link  to  certain
therapies.  The  aforementioned  studies  identiﬁed  the  tie
between  eosinophils  and  a  pathoimmunological  process.10
As  for  the  prognostic  value,  the  relationship  with  the  respi-
ratory  function  and  exacerbations,  two  factors  determining
the  classiﬁcation  of  these  patients,  must  be  identiﬁed.
Although  we  have  seen  that  the  RV  may  be  inﬂu-
enced  by  the  Th210 gene  expression,  FEV1 has  been  the
most  extensively  studied  functional  parameter  in  assessing
COPD  patients.  Several  studies  have  denied  the  relation-
ship  between  eosinophil  count  and  decreased  respiratory
function,  but  a  recent  CHEST12 editorial  highlighted  that
persistent  eosinophilia,  although  unrelated  in  COPD  with
reduced  lung  function  (as  shown  in  the  ECLIPSE  study),  may
be  deleterious  in  the  appropriate  environment.  In  a  cohort  of
patients  with  non-asthmatic  eosinophilic  bronchitis13 (that
included  141  patients  followed  over  10  years),  60%  of  these
patients  relapsed  after  4  weeks  of  ICS  therapy,  the  relapse
rate  being  signiﬁcantly  higher  among  individuals  with  persis-
tent  airway  eosinophilia.  Although  the  disease  did  not  evolve
to  obstruction,  there  was  more  signiﬁcant  dysfunction  of  the
small  airways  in  the  group  with  disease  recurrence.
As  for  exacerbations,  a  recently  published  study14 with
over  80,000  participants  and  7225  patients  identiﬁed  with
COPD  (excluding  patients  diagnosed  with  asthma),  linked  a
total  count  of  eosinophils  above  340  cells/L with  a  twofold
increase  of  exacerbations  during  the  follow-up  period  of  3.3
years.
Therefore,  the  eosinophil  count  has  deﬁnitely  a  progno-
stic  value  in  COPD,  as  it  does  in  the  case  of  asthma.
In  relation  to  the  link  with  therapy,  (we  know  it  does
exist  in  asthmatics),  in  patients  with  COPD  such  evidence  is
becoming  deﬁnitive.  In  a  metanalysis  published  in  2014,15
which  aimed  at  comparing  the  outcomes  of  COPD  patients
with  exacerbations  under  prednisolone  or  the  equivalent
vs.  patients  under  therapy  excluding  systemic  corticosteroid
treatment,  it  was  found  that,  when  patients  were  grouped
according  to  the  count  of  eosinophils  in  the  peripheral  blood
(cut-off  ≥2%),  in  patients  with  ≥2%,  treatment  failure  rate
was  much  higher  in  those  not  treated  with  systemic  cortico-
steroids  during  exacerbation  (66%  vs.  11%).
Other  post  hoc  analyses  of  clinical  trials  showed  that  the
phenotype-oriented  therapy  can  be  relevant.
A  post  hoc  analysis  of  INSPIRE  study16 (conducted  on
patients  with  exacerbations,  with  moderate  to  severe
COPD),  which  compared  two  branches  of  treatment  --
ﬂuticasone  propionate  (FP)  +  salmeterol  against  tiotropium
bromide  -- in  the  group  with  eosinophil  count  in  the  periph-
eral  blood  ≥2%,  showed  that  exacerbation  rate  reduction
was  more  signiﬁcant  in  patients  with  combined  treatment
with  ICS  and  bronchodilator  (BD).17
In  the  post  hoc  analysis  of  ISOLDE18 study  (that  assessed
the  efﬁcacy  of  FP  therapy,  which  included  patients  at  all  lev-
els  of  COPD  severity,  excluding  asthmatics),  FEV1 decrease
in  patients  with  ≥2%  eosinophil  in  the  peripheral  blood  was
signiﬁcantly  lower  in  those  patients  receiving  FP.19
The  post  hoc  analysis  of  FORWARD  study20 (conducted  on
patients  with  severe  COPD  and  a  history  of  exacerbation),281
hich  compared  the  efﬁcacy  of  treatment  with  beclometa-
one/formoterol  against  formoterol,  showed  that  when
atients  were  organised  in  quartiles  of  eosinophil  count  in
he  peripheral  blood,  the  exacerbations  rate  dropped  signif-
cantly  (46%)  in  the  arm  treated  with  the  combined  therapy
f  the  upper  quartile  group  of  patients  (over  280  cells/L).
Finally,  in  a more  recent  study  published  in  Lancet  Respi-
atory  Medicine,21 eosinophil  blood  count  proved  to  be  an
mportant  marker  for  identifying  candidates  for  therapy
pproaches  seeking  to  reduce  exacerbations.  This  post  hoc
nalysis  included  more  than  3000  patients  meeting  ATS/ERS
riteria  for  COPD,  excluding  those  who  were  currently
iagnosed  for  asthma  (but  not  the  ones  with  a  previous
iagnose).  In  approximately  2/3  of  patients  the  count  of
osinophils  in  the  peripheral  blood  was  equal  or  higher  than
%  and  exacerbations  decreased  signiﬁcantly  in  this  patient
roup  when  treatment  included  ICS  (0.91  vs  1.28  exacerba-
ions/patient/year;  p  <  0.0001).
Although  none  of  these  studies  provide  a  mechanistic
xplanation  for  the  added  value  of  ICS  in  eosinophilic  COPD,
uture  results  of  trials  with  biological  treatments  (like  anti-
L5)  will  deliver  further  insight.  Regarding  benralizumab,  an
ssessment  study  of  the  efﬁcacy  of  anti-IL5  in  patients  with
oderate  to  severe  COPD,  although  not  having  found  signiﬁ-
ant  difference  in  the  primary  endpoint  (acute  exacerbation
f  COPD)  in  the  different  eosinophilic  groups,  found  a  clini-
ally  signiﬁcant  improvement  after  anti-IL5  in  patients  with
osinophil  count  ≥200  cells/L.22
Therefore,  as  suggested  by  Bateman  et  al.23 in  a  paper
hat  reviews  the  factors  shared  by  the  clinical  expressions  of
he  obstructive  pathology  (asthma,  COPD  or  ACOS),  the  tax-
nomy  of  obstructive  diseases  must  be  reassessed.  Until  that
appens,  we  suggest  the  use  of  biomarkers  like  eosinophils,
s  the  eosinophilic  phenotype  is  cross-cutting,  with  a  clearly
ore  favourable  response  with  ICS  treatment.
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